| Objective:To analyze the clinical effect of different doses of rosuvastatin calcium on the treatment of coronary heart
disease and hyperlipidemia and the influence on the serum hs-CRP and IMT.Methods:203 patients with coronary heart disease and hyperlipidemia
who were treated in our hospital fromJune 2013 to June 2015 were selected and according to the different doses of rosuvastatin,
the patients were divided into the small dose group (70 cases), the moderate dose group (64 cases) and the large dose group (69 cases),
that were treated with oral administration of rosuvastatin calcium for 5 mg/ d, 10 mg/d and 20 mg/d, respectively. Then the changes of
blood lipids (TC, LDL-C, TG, HDL-C), serum hs-CRP levels and IMT in the three groups were observed and compared before and after
treatment.Results:groups before treatment (P>0.05); Compared with before treatment, the serumlevels of hs-CRP, TG, TC, LDL-C, HDL-C and
IMT in the three groups decreased after treatment, and the differences were statistically significant (P<0.05); The serumlevels of hs-CRP,
TG, TC, LDL-C, HDL-C and IMT of patients in large dose group were lower than those of the small dose group and the moderate dose
group, and the differences were statistically significant (P<0.05); The serum levels of hs-CRP, TG, TC, LDL-C, HDL-C and IMT of patients
in moderate dose group were lower than those of the small dose group, and the differences were statistically significant (P<0.05);Conclusion:Rosuvastatin can improve the blood lipids, decrease the serum levels of hs-CRP levels and IMT in patients with coronary
heart disease and hyperlipidemia, which is worthy of clinical application. |
